Testing a new pill form of arsenic treatment for a rare blood cancer

Plain-English translation of NCT07504458 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new oral (pill) form of arsenic trioxide called QTX-2101, given together with another medication called all-trans retinoic acid, in adults with newly diagnosed acute promyelocytic leukemia (APL). The study will compare this new pill combination to the standard intravenous (IV) arsenic treatment that patients typically receive. Researchers want to see if the medication works just as well when taken by mouth instead of through an IV.

Currently, patients with this rare blood cancer must receive arsenic treatment through an IV, which requires frequent hospital or clinic visits. This trial exists to find out whether taking the treatment as a pill at home could be just as effective, making it easier and more convenient for patients while still achieving good results.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been newly diagnosed with low-risk or intermediate-risk acute promyelocytic leukemia, confirmed by genetic testing
you are willing to take oral medication and attend regular study visits
you are able to use contraception if applicable and able to swallow pills safely
you can commit to following the study's treatment plan and attending all required appointments

You likely don't qualify if…

you have serious heart rhythm problems, including long QT syndrome or dangerous arrhythmias
you have leukemia that has spread to your brain or central nervous system
you are pregnant, breastfeeding, or unwilling to use birth control
you have severe swallowing difficulties, serious digestive problems, or an allergy to arsenic or retinoic acid
you have uncontrolled infections or severe disease in other organs that would make the study unsafe

What participation looks like

You would be randomly assigned to take either the new oral pill form of arsenic treatment or the traditional IV version, both combined with another oral medication. You would attend regular study visits to receive your medication, have blood tests and heart monitoring (ECG), and be checked for any side effects. The study will track how well the medication works and how safe it is over the course of your treatment.

AI-generated summary from trial data · Jul 16, 2026 · Not medical advice

Trial locations(14 sites)

United States

Quetzal Site 1, Duarte, California

Quetzal Site 7, Los Angeles, California

Quetzal Site 5, Stanford, California

Quetzal Site 13, Augusta, Georgia

Quetzal Site 4, Buffalo, New York